TORRANCE, Calif.--(BUSINESS WIRE)--Celprogen Inc., a leader in the Stem Cell Research and Therapeutics industry for the development of stem cell technologies for regenerative medicine, today announced that they have developed a novel pharmacological Inhibitor CEP1430 synthetic molecule that is capable of inhibiting the growth and proliferation of the human pancreatic cancer tumor. This molecule can be administrated by the following methods: intravenous and intra-peritoneal. The molecule CEP1430 will be presented at the American Association for Cancer Research Annual Meeting in Philadelphia, Tuesday, April 21, 2015, 1:00 PM - 5:00 PM; Therapeutics Targeting Cancer Stem Cells.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
